Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 24;15(11):2523.
doi: 10.3390/pharmaceutics15112523.

Caco-2 Cell Line Standardization with Pharmaceutical Requirements and In Vitro Model Suitability for Permeability Assays

Affiliations
Review

Caco-2 Cell Line Standardization with Pharmaceutical Requirements and In Vitro Model Suitability for Permeability Assays

Marta Kus et al. Pharmaceutics. .

Abstract

The Caco-2 cell line derived from human colon carcinoma is commonly used to assess the permeability of compounds in in vitro conditions. Due to the significant increase in permeability studies using the Caco-2 cell line in recent years, the need to standardize this biological model seems necessary. The pharmaceutical requirements define only the acceptance criteria for the validation of the Caco-2 cell line and do not specify the protocol for its implementation. Therefore, the aim of this study is to review the conditions for permeability studies across the Caco-2 monolayer reported in the available literature concerning validation guidelines. We summarized the main aspects affecting the validation process of the Caco-2 cell line, including the culture conditions, cytotoxicity, cell differentiation process, and monolayer transport conditions, and the main conclusions may be useful in developing individual methods for preparing the cell line for validation purposes and further permeability research.

Keywords: Caco-2 cell line; biowaiver; drug permeability; pharmaceutical requirements; validation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Alqahtani M.S., Kazi M., Alsenaidy M.A., Ahmad M.Z. Advances in Oral Drug Delivery. Front. Pharmacol. 2021;12:618411. doi: 10.3389/fphar.2021.618411. - DOI - PMC - PubMed
    1. Hua S. Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract—Influence of Physiological, Pathophysiological and Pharmaceutical Factors. Front. Pharmacol. 2020;11:524. doi: 10.3389/fphar.2020.00524. - DOI - PMC - PubMed
    1. Lou J., Duan H., Qin Q., Teng Z., Gan F., Zhou X., Zhou X. Advances in Oral Drug Delivery Systems: Challenges and Opportunities. Pharmaceutics. 2023;15:484. doi: 10.3390/pharmaceutics15020484. - DOI - PMC - PubMed
    1. Pond S.M., Tozer T.N. First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. 1984;9:1–25. doi: 10.2165/00003088-198409010-00001. - DOI - PubMed
    1. Doherty M.M., Pang K.S. First-pass effect: Significance of the intestine for absorption and metabolism. Drug Chem. Toxicol. 1997;20:329–344. doi: 10.3109/01480549709003891. - DOI - PubMed

LinkOut - more resources